Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01570309 · ClinicalTrials.gov registry record · NA

Vitamin D Repletion in Coronary Artery Disease

A NA study of Coronary Artery Disease and Inflammation, sponsored by Seth I. Sokol, M.D..

Completed
Registry status
NA
Development phase
96
Enrollment target
2
Study locations

NCT01570309 is a NA study of Coronary Artery Disease and Inflammation that has completed, run by Seth I. Sokol, M.D.. The registered enrollment target is 96 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01570309, a NA study of Coronary Artery Disease and Inflammation, has completed, sponsored by Seth I. Sokol, M.D..

COMPLETED
Registry status
NA
Development phase
96 participants
Enrollment target
2
Study locations

Study Summary

Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and prevalent cardiovascular disease. Vit D insufficiency remains very prevalent in free living populations in the United States especially in urban, and multi-ethnic low income Northern cities.To date, prospective randomized trials using Vit D supplementation to modify CVD risk and evaluate outcomes have not been performed. The investigators propose a double-blind, randomized wait-list control trial in subjects with Coronary Artery Disease (CAD) and Vit D deficiency with two specific aims. Specific aim 1 is to measure endothelial function using reactive hyperemia peripheral arterial tonometry (RH-PAT) before and after treatment with Vit D replacement therapy. Specific Aim 2 is to measure levels of inflammation before and after treatment with Vit D replacement therapy. These aims will test the hypotheses that Vit D repletion will improve endothelial function and reduce the levels of detectable inflammation in the plasma of these subjects.

Interventions

  • DRUG Ergocalciferol
  • OTHER Sugar pill

Study Locations (2)

New York

  • Jacobi Medical Center - The Bronx
  • Montefiore Medical Center / Weiler division - The Bronx

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2008-08
Est. Completion 2011-03
Phase NA

Sponsor

Seth I. Sokol, M.D.

1 total trials

What the Registry Record Tells You About NCT01570309

The ClinicalTrials.gov registry entry for NCT01570309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (93% lower). The listed sponsor is Seth I. Sokol, M.D., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Ergocalciferol is the first listed.

NCT01570309 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01570309 about?

NCT01570309 is a clinical study titled "Vitamin D Repletion in Coronary Artery Disease". Vitamin D (Vit D) status is an emerging risk marker of great interest in cardiovascular disease (CVD). Lower serum levels of Vit D are associated with both cardiac risk factors and prevalent cardiovascular disease. Vit D insufficiency remains very prevalent in free living populations in the United S...

What is the current status of trial NCT01570309?

This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2008-08. Estimated completion is 2011-03.

What conditions does trial NCT01570309 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Inflammation, Vitamin D Deficiency, Endothelial Dysfunction.

What interventions are being tested in trial NCT01570309?

The interventions under investigation include: Ergocalciferol (DRUG), Sugar pill (OTHER).

Who is sponsoring clinical trial NCT01570309?

This trial is sponsored by Seth I. Sokol, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01570309 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.